Is Re­gen­eron los­ing its R&D mys­tique? An­a­lyst dis­counts big biotech’s run­ner-up de­vel­op­ment strat­e­gy in an in­creas­ing­ly com­modi­tized world

No­body diss­es Re­gen­eron.

Af­ter build­ing a megablock­buster out of Eylea and com­mand­ing mas­sive re­spect for their new block­buster Dupix­ent, part­nered with Sanofi, bow­ing to com­pa­ny founders George Yan­copou­los and Leonard Schleifer has be­come re­flex­ive be­hav­ior in the in­dus­try. They did it their way, with bil­lions to show for it.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER